Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogenetic risk
Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogenetic risk
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM
UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma
Long-term disease control in multiple myeloma by in-class transitioning: A community-based study
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Treating acute lymphoblastic leukaemia in the era of COVID-19
COVID-19 and impact on gynecologic oncology practice in India: Results of a nationwide survey
The future of PARP inhibitors in prostate cancer
Managing acute myeloid leukaemia during the COVID-19 pandemic
Meet the Expert: Daniel Seymour
Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice